

## ASX Announcement

# Results of 2023 Annual General Meeting

**SYDNEY Australia, 8 November 2023:** Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (the **Company**), provides the following information in relation to the resolutions put to the shareholders of the Company at its Annual General Meeting held today at 9:00am (AEDT).

All resolutions were decided by way of poll and were passed with the exception of Resolution 1 which was not passed. As more than 25% of the votes cast on Resolution 1 were against the adoption of the 2023 Remuneration Report, this constitutes a ‘first strike’ for purposes of the *Corporations Act 2001* (Cth).

In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the *Corporations Act 2001* (Cth), a summary of the proxy votes and the number of votes cast on each resolution in the poll is attached.

This announcement has been approved for release by Recce Pharmaceuticals Board.

## About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: **RCE**, FSE: **R9Q**) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.



ASX: RCE, FSE: R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 T +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

# Disclosure of Proxy Votes

## Recce Pharmaceuticals Ltd

Annual General Meeting

Wednesday, 08 November 2023



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	34,929,009	8,934,368 25.58%	21,733,319 62.22%	67,093	4,261,322 12.20%	15,534,752 41.64%	21,772,862 58.36%	67,093	-
2 Re-election of Michele Dilizia as Director	P	38,681,493	34,255,430 88.56%	176,741 0.46%	25,472	4,249,322 10.99%	41,209,318 99.57%	176,741 0.43%	35,472	Passed
3 Re-election of Dr Justin Ward as Director	P	38,403,893	21,410,205 55.75%	12,744,366 33.19%	303,072	4,249,322 11.06%	28,364,093 68.98%	12,754,366 31.02%	303,072	Passed
4 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	38,672,680	33,952,574 87.79%	456,139 1.18%	34,285	4,263,967 11.03%	40,861,564 98.78%	505,682 1.22%	54,285	Passed
5 Ratification of Prior Issue of Placement Shares	P	25,911,655	21,325,691 82.30%	331,997 1.28%	12,793,012	4,253,967 16.42%	28,254,681 98.70%	371,540 1.30%	12,793,012	Passed
6 Adoption of Employee Incentive Plan	P	30,231,399	16,940,400 56.04%	8,835,111 29.22%	3,635,486	4,455,888 14.74%	23,692,040 72.73%	8,884,654 27.27%	3,655,486	Passed
7 Approval of Issue of Shortfall Shares to Dr John Prendergast, Director of the Company	P	38,548,663	33,998,828 88.20%	300,015 0.78%	158,302	4,249,820 11.02%	40,673,671 99.17%	339,558 0.83%	158,302	Passed
8 Approval of Issue of Shortfall Shares to Dr Alan Dunton, Director of the Company	P	38,548,663	34,036,828 88.30%	262,015 0.68%	158,302	4,249,820 11.02%	40,901,671 99.27%	301,558 0.73%	158,302	Passed



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval of Issue of Shortfall Shares to Dr Justin Ward, Director of the Company	P	38,383,583	33,836,748 88.15%	297,015 0.77%	323,382	4,249,820 11.07%	40,761,591 99.18%	336,558 0.82%	323,382	Passed

